Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip

Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip

In 2018, the world of functional mitral regurgitation changed with the presentation of two trials – Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percuta...

Full description

Bibliographic Details
Main Authors: Kimberly Atianzar, Ming Zhang, Zachary Newhart, Sameer Gafoor
Format: Article
Language:English
Published: Radcliffe Medical Media 2019-01-01
Series:Interventional Cardiology: Reviews, Research, Resources
Online Access:https://www.icrjournal.com/articleindex/icr.2018.40.1
id doaj-9f2921249acb40c893f2e75df11586de
record_format Article
spelling doaj-9f2921249acb40c893f2e75df11586de2021-10-09T16:00:57ZengRadcliffe Medical MediaInterventional Cardiology: Reviews, Research, Resources1756-14771756-14852019-01-01141454710.15420/icr.2018.40.1Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClipKimberly Atianzar0Ming Zhang1Zachary Newhart2Sameer Gafoor3Medical College of Georgia at Augusta University, Augusta, GA, US; Swedish Heart and Vascular Institute, Seattle, WA, USSwedish Heart and Vascular Institute, Seattle, WA, USSwedish Heart and Vascular Institute, Seattle, WA, USSwedish Heart and Vascular Institute, Seattle, WA, US; CardioVascular Center Frankfurt, Frankfurt, GermanyIn 2018, the world of functional mitral regurgitation changed with the presentation of two trials – Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.https://www.icrjournal.com/articleindex/icr.2018.40.1
collection DOAJ
language English
format Article
sources DOAJ
author Kimberly Atianzar
Ming Zhang
Zachary Newhart
Sameer Gafoor
spellingShingle Kimberly Atianzar
Ming Zhang
Zachary Newhart
Sameer Gafoor
Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
Interventional Cardiology: Reviews, Research, Resources
author_facet Kimberly Atianzar
Ming Zhang
Zachary Newhart
Sameer Gafoor
author_sort Kimberly Atianzar
title Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
title_short Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
title_full Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
title_fullStr Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
title_full_unstemmed Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
title_sort why did coapt win while mitra-fr failed? defining the appropriate patient population for mitraclip
publisher Radcliffe Medical Media
series Interventional Cardiology: Reviews, Research, Resources
issn 1756-1477
1756-1485
publishDate 2019-01-01
description In 2018, the world of functional mitral regurgitation changed with the presentation of two trials – Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.
url https://www.icrjournal.com/articleindex/icr.2018.40.1
work_keys_str_mv AT kimberlyatianzar whydidcoaptwinwhilemitrafrfaileddefiningtheappropriatepatientpopulationformitraclip
AT mingzhang whydidcoaptwinwhilemitrafrfaileddefiningtheappropriatepatientpopulationformitraclip
AT zacharynewhart whydidcoaptwinwhilemitrafrfaileddefiningtheappropriatepatientpopulationformitraclip
AT sameergafoor whydidcoaptwinwhilemitrafrfaileddefiningtheappropriatepatientpopulationformitraclip
_version_ 1716830467055943680

Similar Items